Physician profile
Christopher Y Chow
NPI 1417938804
$123,275.94
in general payments reported to CMS, 2019-2025
23 companies · $29K in 2025
The $29K reported for 2025 was more than what 97% of Cornea and External Diseases Specialist providers received nationally (typical 2025 total: $477).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,104 · 2020: $3,970 · 2021: $847 · 2022: $1,068 · 2023: $20K · 2024: $61K · 2025: $29K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $75K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $18K · Travel and Lodging: $9,900 · Food and Beverage: $5,025 · Consulting Fee: $1,063.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $75,250.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $18,050.00 |
| Travel and Lodging | $9,900.24 |
| Food and Beverage | $5,024.78 |
| Consulting Fee | $1,062.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $87,753.28 | 2022-2025 | Miebo, Xiidra, Blink Nutritears |
| Oyster Point Pharma, INC. | $20,140.34 | 2024-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Shire North American Group INC | $7,162.67 | 2019 | |
| Novartis Pharmaceuticals Corporation | $4,080.20 | 2019-2022 | |
| Allergan, INC. | $713.67 | 2019-2022 | |
| Abbvie INC. | $507.38 | 2022-2025 | Durysta |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $377.44 | 2019-2020 | |
| Alcon Vision LLC | $375.64 | 2022-2025 | Tryptyr, Rocklatan, Eysuvis |
| Biotissue Holdings INC. | $350.30 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $342.50 | 2019-2025 | Cequa |
| Dompe US, INC. | $340.61 | 2019-2025 | Oxervate |
| Tarsus Pharmaceuticals, INC. | $277.50 | 2024-2025 | Xdemvy |
| Kala Pharmaceuticals, INC. | $251.82 | 2019-2022 | |
| Eyepoint US, INC. | $173.12 | 2019 | |
| Glaukos Corporation | $153.30 | 2021-2024 | Photrexa |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Enterprises LLC | $94.68 | 2019 | |
| Mallinckrodt Hospital Products INC. | $51.41 | 2021 | |
| Ocular Therapeutix, INC. | $39.67 | 2023 | Dextenza |
| Regeneron Healthcare Solutions, INC. | $22.40 | 2024 | Eylea, Eylea Hd |
| Amgen INC. | $19.90 | 2025 | Tepezza |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Eyevance Pharmaceuticals LLC | $14.63 | 2022 | |
| Akorn Operating Company LLC | $14.08 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Chow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.